In today’s ACT Brief, we examine how the FDA’s CNPV Program is reshaping operational planning and accelerated submission ...

Explore the challenges sponsors and CROs face in maintaining clinical reference data, uncover the hidden costs of traditional upkeep models, and see how integrated data solutions can streamline ...

Objective To quantify the time lag between biomedical articles and the studies they describe as “recent,” a term widely used to imply timeliness despite rarely reflecting the actual age of the cited ...

Researchers sought to determine whether zanubrutinib plus obinutuzumab would be effective in treating patients with R/R FL.

This live blog is now closed. A five-judge Bench of the Supreme Court on Thursday (November 20, 2025) answered the 16th Presidential Reference the country has witnessed by opining that the judiciary ...

Doctors and researchers try to understand what medications a person has taken by asking patients directly or by looking at medical records. But this information is often incomplete.

The Food and Drug Administration (FDA) has approved Breyanzi ® (lisocabtagene maraleucel; liso-cel) for the treatment of adult patients with relapsed or refractory (R/R) marginal zone lymphoma (MZL) ...

A section of booth-level officers on Saturday (November 15, 2025) raised concerns with increasing work pressure in light of the ongoing Special Intensive Revision (SIR) of West Bengal’s electoral ...

SACRAMENTO — The question for many schools about using large language models (LLMs) has shifted from “if” to “how,” and there are no shortage of technology vendors bidding for their attention. But for ...

Bank of America Leveraged Finance Conference December 2, 2025 7:30 AM ESTCompany ParticipantsDoug Garis - Executive VP ...

At their first public press conference, Fire Point founders and Ukraine’s military highlighted the success of their ...

Kelonia Therapeutics' KLN-1010 has shown promising early results in a phase 1 trial for relapsed or refractory multiple ...